HRP20150026T1 - 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti - Google Patents

8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti Download PDF

Info

Publication number
HRP20150026T1
HRP20150026T1 HRP20150026AT HRP20150026T HRP20150026T1 HR P20150026 T1 HRP20150026 T1 HR P20150026T1 HR P20150026A T HRP20150026A T HR P20150026AT HR P20150026 T HRP20150026 T HR P20150026T HR P20150026 T1 HRP20150026 T1 HR P20150026T1
Authority
HR
Croatia
Prior art keywords
compound
compound according
crystalline form
treatment
hydroxymethyl
Prior art date
Application number
HRP20150026AT
Other languages
English (en)
Croatian (hr)
Inventor
Holly Esken
Beth Adams Norton
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of HRP20150026T1 publication Critical patent/HRP20150026T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20150026AT 2008-12-08 2009-12-07 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti HRP20150026T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12059608P 2008-12-08 2008-12-08
EP09832421.3A EP2370440B1 (en) 2008-12-08 2009-12-07 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione 2-amino-2-(hydroxymethyl)-1,3-propanediol anhydrate for the treatment of diseases
PCT/US2009/066941 WO2010068581A1 (en) 2008-12-08 2009-12-07 Novel compounds

Publications (1)

Publication Number Publication Date
HRP20150026T1 true HRP20150026T1 (hr) 2015-02-13

Family

ID=42243044

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150026AT HRP20150026T1 (hr) 2008-12-08 2009-12-07 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti

Country Status (22)

Country Link
US (3) US9163024B2 (https=)
EP (1) EP2370440B1 (https=)
JP (1) JP5666464B2 (https=)
KR (1) KR101743783B1 (https=)
CN (1) CN102245606B (https=)
AU (1) AU2009324811B2 (https=)
BR (1) BRPI0922134A2 (https=)
CA (1) CA2746316C (https=)
CY (1) CY1116032T1 (https=)
DK (1) DK2370440T3 (https=)
EA (1) EA020037B1 (https=)
ES (1) ES2527354T3 (https=)
HR (1) HRP20150026T1 (https=)
IL (1) IL213032A (https=)
MX (1) MX2011006022A (https=)
PL (1) PL2370440T3 (https=)
PT (1) PT2370440E (https=)
RS (1) RS53777B1 (https=)
SI (1) SI2370440T1 (https=)
SM (1) SMT201500012B (https=)
WO (1) WO2010068581A1 (https=)
ZA (1) ZA201103397B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1781657T3 (pl) * 2004-02-14 2013-08-30 Glaxosmithkline Ip Dev Ltd Leki o aktywności wobec receptora HM74A
ES2401128T3 (es) 2005-08-10 2013-04-17 Glaxosmithkline Llc Derivados de xantina como agonistas selectivos de HM74A
EA201491749A1 (ru) * 2012-03-22 2015-01-30 ТРАНСТЕК ФАРМА, ЭлЭлСи Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение
CN121219290A (zh) 2023-02-27 2025-12-26 珊顿医药科技新加坡公司 化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657327A (en) * 1970-06-01 1972-04-18 Upjohn Co Prostaglandin salts of tris(hydroxymethyl)aminomethane
US4647585A (en) 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
EP1237851A4 (en) * 1999-12-15 2004-06-23 Smithkline Beecham SALES OF I CIS / I-4-CYANO-4-3- (CYCLOPENTYLOXY) -4-METHOXYPHENYL] CYCLHEXAN-1-CARBONIC ACID
US20030013905A1 (en) 2002-06-10 2003-01-16 Huang Guishu Kris Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
PL1781657T3 (pl) 2004-02-14 2013-08-30 Glaxosmithkline Ip Dev Ltd Leki o aktywności wobec receptora HM74A
GB0423568D0 (en) * 2004-10-22 2004-11-24 Smithkline Beecham Corp Novel compounds
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
ES2401128T3 (es) 2005-08-10 2013-04-17 Glaxosmithkline Llc Derivados de xantina como agonistas selectivos de HM74A

Also Published As

Publication number Publication date
EA201170783A1 (ru) 2011-12-30
PL2370440T3 (pl) 2015-05-29
MX2011006022A (es) 2011-06-28
EP2370440A4 (en) 2012-05-30
US20110251218A1 (en) 2011-10-13
AU2009324811A1 (en) 2011-06-23
JP2012511028A (ja) 2012-05-17
ES2527354T3 (es) 2015-01-22
EA020037B1 (ru) 2014-08-29
RS53777B1 (sr) 2015-06-30
CA2746316A1 (en) 2010-06-17
CN102245606A (zh) 2011-11-16
SMT201500012B (it) 2015-05-03
AU2009324811B2 (en) 2013-01-24
DK2370440T3 (en) 2014-12-08
EP2370440A1 (en) 2011-10-05
US20150366870A1 (en) 2015-12-24
EP2370440B1 (en) 2014-11-12
KR101743783B1 (ko) 2017-06-05
PT2370440E (pt) 2015-01-14
CA2746316C (en) 2017-01-03
JP5666464B2 (ja) 2015-02-12
CN102245606B (zh) 2014-08-20
ZA201103397B (en) 2012-01-25
IL213032A0 (en) 2011-07-31
BRPI0922134A2 (pt) 2015-08-18
CY1116032T1 (el) 2017-01-25
US20170027945A1 (en) 2017-02-02
WO2010068581A1 (en) 2010-06-17
KR20110097816A (ko) 2011-08-31
IL213032A (en) 2015-02-26
SI2370440T1 (sl) 2015-02-27
US9163024B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
CZ30899A3 (cs) Substituovaný pyridin a bifenyl jako antihypercholesterinemické, antihyperlipoproteinemické a antihyperglykemické přípravky
FI4157832T3 (fi) Glp-1r-agonistien suola- ja kidemuotoja ja niiden käyttötarkoituksia
HRP20150026T1 (hr) 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti
CN115244056A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
JP2021521265A (ja) Ｇｌｐ−１受容体アゴニストおよびその使用
KR20190094433A (ko) Glp-1 수용체 작용제 및 이의 용도
EP2041072B1 (en) Cxcr2 antagonists
JP2009509932A5 (https=)
NO343371B1 (no) Nye forbindelser med DGAT1-aktivitet, farmasøytiske sammensetninger inneholdende slike og anvendelse derav
KR20110055735A (ko) 박테리아 감염 치료에 적용하기 위한 유기 화합물
CA2621949A1 (en) Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JP2007500720A5 (https=)
NO20056056L (no) N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer
JP2011528362A5 (https=)
KR102563111B1 (ko) Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
JP5993472B2 (ja) ニコチン性アセチルコリン受容体の陽性アロステリックモジュレーター
AU2007210002A1 (en) Compounds and compositions as PPAR modulators
WO2014025942A1 (en) Nmda receptor modulators and uses related thereto
JP4738812B2 (ja) 二官能性フェニルイソ（チオ）シアナート、それらを製造するための方法および中間体
WO2011151436A2 (en) Novel compounds, method for use them and pharmaceutical composition containing them
JP2008500354A (ja) Ｐｐａｒモジュレーターとしての化合物および組成物
AU2006311524A1 (en) Compounds and compositions as PPAR modulators
JP2012511028A5 (https=)
JP2007537289A (ja) Ｐｐａｒモジュレーターとしての化合物および組成物
KR20250086780A (ko) Cx3cr1 조절제로서의 2,4,6-삼중치환된 1,3,5-트리아진